Journal of Clinical Endocrinology & Metabolism, Vol 80, 878-884, Copyright © 1995 by Endocrine Society

ARTICLES

Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas

S Ezzat, HS Smyth, L Ramyar and SL Asa
Department of Endocrinology, University of Toronto, Ontario, Canada.

Basic fibroblast growth factor (bFGF) is a potent mitogenic and angiogenic factor that is known to regulate GH, PRL, and TSH secretion. Sequences within a bFGF gene family member have been detected in transforming DNA samples derived from human PRL-secreting tumors. Furthermore, elevated serum concentrations of bFGF have been noted in patients with multiple endocrine neoplasia-1. To further examine the significance of bFGF in sporadic human pituitary adenomas, we investigated the expression of bFGF by these tumors. Using an enzyme- linked immunoassay that recognizes all 16-24 kilodalton molecular mass forms of bFGF, we measured circulating serum concentrations in 21 patients with sporadic pituitary adenomas; they ranged from less than 0.5-84 pg/mL and declined following surgical adenomectomy. To confirm the pituitary source of this growth factor, we determined in vitro bFGF release from 43 adenomas (10 GH, 7 PRL, 10 ACTH, 14 gonadotrope adenomas/oncocytomas, and 2 silent subtype 3 adenomas). bFGF was present with wide variability (0.75-2100 pg/24 h.10(5) cells) in conditioned culture media of all adenomas examined. The adenohypophysial source of this growth factor was further demonstrated by the reverse hemolytic plaque assay. Variable bFGF messenger RNA expression was identified by the reverse-transcription polymerase chain reaction technique in 9 functional (2 PRL, 5 GH, 2 ACTH) and 7 nonfunctional (1 oncocytoma, 2 null cell, 2 gonadotrope, 2 Silent Subtype 3) adenomas examined. bFGF levels were unaltered in vitro following hypothalamic hormone stimulation/inhibition. The lack of a bFGF signal peptide sequence and hypothalamic hormone-independence suggest that secretion of this factor may be independent of pituitary hormone regulation. Immunocytochemistry failed to localize bFGF in tumors that released this factor in vitro, suggesting that storage of this peptide does not correlate with its synthesis and release. In conclusion, the heterogenous expression of bFGF suggests that it may play a specific and selective role in the tumorigenic process of some pituitary adenomas.

This article has been cited by other articles:

				X. Zhu, S. L. Asa, and S. Ezzat Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia Clin. Cancer Res., April 1, 2008; 14(7): 1984 - 1996. [Abstract] [Full Text] [PDF]

				C. Cristina, G. Diaz-Torga, A. Gongora, M. C. Guida, M. I. Perez-Millan, A. Baldi, and D. Becu-Villalobos Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1341 - E1351. [Abstract] [Full Text] [PDF]

				X. Zhu, K. Lee, S. L. Asa, and S. Ezzat Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells Am. J. Pathol., May 1, 2007; 170(5): 1618 - 1628. [Abstract] [Full Text] [PDF]

				S. Ezzat, L. Zheng, D. Winer, and S. L. Asa Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications Mol. Endocrinol., November 1, 2006; 20(11): 2965 - 2975. [Abstract] [Full Text] [PDF]

				S Ezzat and S L Asa The molecular pathogenetic role of cell adhesion in endocrine neoplasia J. Clin. Pathol., November 1, 2005; 58(11): 1121 - 1125. [Abstract] [Full Text] [PDF]

				K. Chaturvedi and D. K. Sarkar Mediation of Basic Fibroblast Growth Factor-Induced Lactotropic Cell Proliferation by Src-Ras-Mitogen-Activated Protein Kinase p44/42 Signaling Endocrinology, April 1, 2005; 146(4): 1948 - 1955. [Abstract] [Full Text] [PDF]

				S. Ezzat, L. Zheng, and S. L. Asa Pituitary Tumor-Derived Fibroblast Growth Factor Receptor 4 Isoform Disrupts Neural Cell-Adhesion Molecule/N-Cadherin Signaling to Diminish Cell Adhesiveness: A Mechanism Underlying Pituitary Neoplasia Mol. Endocrinol., October 1, 2004; 18(10): 2543 - 2552. [Abstract] [Full Text] [PDF]

				Z. R. Qian, T. Sano, S. L. Asa, S. Yamada, H. Horiguchi, T. Tashiro, C. C. Li, M. Hirokawa, K. Kovacs, and S. Ezzat Cytoplasmic Expression of Fibroblast Growth Factor Receptor-4 in Human Pituitary Adenomas: Relation to Tumor Type, Size, Proliferation, and Invasiveness J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1904 - 1911. [Abstract] [Full Text] [PDF]

				H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF]

				A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF]

				S. Ezzat, S. Yu, and S. L. Asa Ikaros Isoforms in Human Pituitary Tumors: Distinct Localization, Histone Acetylation, and Activation of the 5' Fibroblast Growth Factor Receptor-4 Promoter Am. J. Pathol., September 1, 2003; 163(3): 1177 - 1184. [Abstract] [Full Text] [PDF]

				S. Yu, S. L. Asa, R. J. Weigel, and S. Ezzat Pituitary Tumor AP-2{alpha} Recognizes a Cryptic Promoter in Intron 4 of Fibroblast Growth Factor Receptor 4 J. Biol. Chem., May 23, 2003; 278(22): 19597 - 19602. [Abstract] [Full Text] [PDF]

				S. Yu, L. Zheng, S. L. Asa, and S. Ezzat Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E490 - E495. [Abstract] [Full Text] [PDF]

				S. Yu, S. L. Asa, and S. Ezzat Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary Mol. Endocrinol., May 1, 2002; 16(5): 1069 - 1078. [Abstract] [Full Text] [PDF]

				S. L. Asa, L. Ramyar, P. R. Murphy, A. W. Li, and S. Ezzat The Endogenous Fibroblast Growth Factor-2 Antisense Gene Product Regulates Pituitary Cell Growth and Hormone Production Mol. Endocrinol., April 1, 2001; 15(4): 589 - 599. [Abstract] [Full Text]

				S. L. Asa and S. Ezzat The Cytogenesis and Pathogenesis of Pituitary Adenomas Endocr. Rev., December 1, 1998; 19(6): 798 - 827. [Abstract] [Full Text]

				I. Shimon and S. Melmed Pituitary Tumor Pathogenesis J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1675 - 1681. [Full Text] [PDF]

				D. Ray and S. Melmed Pituitary Cytokine and Growth Factor Expression and Action Endocr. Rev., April 1, 1997; 18(2): 206 - 228. [Abstract] [Full Text]

				S. A. A. Abbass, S. L. Asa, and S. Ezzat Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1160 - 1166. [Abstract] [Full Text] [PDF]